Deepsight
DeepSight Technology, founded in 2019 by Nader Sadrzadeh, is a medical device company headquartered in the San Francisco Bay Area with additional offices in St.
Profile
DeepSight develops advanced ultrasound systems that improve diagnostic imaging accuracy and patient care.
DeepSight Technology, founded in 2019 by Nader Sadrzadeh, is a medical device company headquartered in the San Francisco Bay Area with additional offices in St. Louis, Missouri. The company specializes in advanced ultrasound solutions, aiming to reinvent diagnostic imaging with proprietary sensor technology that delivers significantly higher sensitivity and clarity compared to conventional ultrasound systems.
DeepSight's flagship products include the NeedleVue™ Ultrasound System, OnPoint™ Imaging, and EchoLux™ Ultrasound System, which leverage patented hardware, software, and AI algorithms to enhance diagnostic accuracy and patient care. In October 2021, DeepSight raised $25 million in a Series A funding round led by Deerfield Management Company, with participation from Wing, Alter Venture Partners, and Time BioVentures. The company has since expanded its leadership team, appointing Dr.
Diku Mandavia as Chief Medical Officer in January 2025 and Dr. Bradford Wood as Vice President of Strategic Partnerships in October 2025. DeepSight's technology has the potential to improve a range of imaging procedures, from needle guidance to diagnostic ultrasound, with applications in both non-invasive and invasive medical imaging. The company continues to focus on clinical validation and commercialization, aiming to bring its transformative technology to hospitals and healthcare providers globally.
Who buys this
- Hospitals and healthcare providers
- Research institutions
- Medical device distributors
- Specialized clinics
- Academic medical centers
Strengths and what to watch
Strengths
- Proprietary sensor technology delivering 100 times higher sensitivity than conventional ultrasound systems
- Strong leadership team with deep expertise in medical imaging and clinical research
- Backed by $25 million Series A funding from reputable healthcare investors
Watch for
- High dependency on clinical validation and regulatory approvals for new products
- Potential challenges in scaling commercialization efforts globally
- Competition from established medical imaging companies with broader product portfolios
Recent moves
Key Information
- Founded
- 2019
- Headquarters
- San Francisco Bay Area
Frequently Asked Questions
What is DeepSight Technology?
DeepSight is a medical device company founded in 2019, specializing in advanced ultrasound systems. Their proprietary sensor technology offers 100x higher sensitivity than conventional ultrasound, improving diagnostic imaging accuracy. Headquartered in the San Francisco Bay Area, they've raised $25M in Series A funding to commercialize their technology globally.
How does DeepSight's ultrasound compare to traditional systems?
DeepSight's patented ultrasound systems deliver significantly higher sensitivity and clarity through proprietary sensor technology. Their NeedleVue™ and EchoLux™ systems leverage AI algorithms to enhance imaging precision, making them particularly effective for needle guidance and diagnostic procedures compared to conventional ultrasound equipment.
Who invested in DeepSight's Series A funding round?
In October 2021, DeepSight raised $25 million in Series A funding led by Deerfield Management Company. The round included participation from Wing, Alter Venture Partners, and Time BioVentures, supporting the company's clinical validation and commercialization efforts for its advanced ultrasound technology.
What are DeepSight's main ultrasound products?
DeepSight's flagship products include the NeedleVue™ Ultrasound System for precision guidance, OnPoint™ Imaging for diagnostic clarity, and EchoLux™ Ultrasound System for enhanced sensitivity. These systems combine proprietary hardware, software, and AI algorithms to improve medical imaging across various clinical applications.
Who leads DeepSight's medical and strategic initiatives?
Dr. Diku Mandavia serves as Chief Medical Officer since January 2025, while Dr. Bradford Wood joined as VP of Strategic Partnerships in October 2025. Their expertise strengthens DeepSight's clinical research and commercialization strategies for advanced ultrasound technology in healthcare markets.
What challenges does DeepSight face in the ultrasound market?
DeepSight must navigate clinical validation processes, regulatory approvals, and global commercialization against established competitors. While their technology offers superior sensitivity, scaling distribution and competing with broader medical imaging portfolios present ongoing challenges for market penetration and adoption.
Sources
- www.prnewswire.com — $25 million Series A funding round led by Deerfield Management Company
- www.prnewswire.com — Appointment of Dr. Diku Mandavia as Chief Medical Officer
- www.prnewswire.com — Appointment of Dr. Bradford Wood as VP of Strategic Partnerships
- www.prnewswire.com — Showcase of NeedleVue™ platform at SIR 2026